Incyte's INCA033989 shows spleen, symptom and anemia responses in Phase 1 myelofibrosis studies
Bitget2026/11/04 14:07- Incyte will present new hematology data at the American Society of Hematology meeting in New Orleans, December 12-15, 2026.
- Phase 1 INCA033989 results showed improved spleen enlargement, symptoms and anemia in myelofibrosis patients, with favorable tolerability in those without prior JAK-inhibitor treatment.
- In essential thrombocythemia, Phase 1 studies showed INCA033989 produced molecular responses and restored normal blood cell production, extending previously presented datasets.
- Long-term Phase 1/2 latarcibart results will assess bleeding prevention in adolescents and adults with von Willebrand disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
